

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

四川科倫博泰生物醫藥股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 6990)

**TERMINATION OF DISCLOSEABLE TRANSACTION
IN RELATION TO
SUBSCRIPTION FOR WEALTH MANAGEMENT PRODUCT**

Reference is made to the announcement of Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the “**Company**”) dated January 6, 2026 (the “**Announcement**”) in relation to, among other things, the subscription for BOC Structured Deposit II in the principal amount of RMB980 million pursuant to the BOC Structured Deposit Agreement II (the “**Subscription**”). Unless otherwise defined, terms used in this announcement shall have the same meanings as those defined in the Announcement.

The board (the “**Board**”) of directors (“**Directors**”) of the Company hereby announces that the Company has terminated the Subscription on January 7, 2026. As such termination was effected within the investment cooling-off period stipulated in the BOC Structured Deposit Agreement II, no payment will be made by the Company for the Subscription and no other charges or penalties will be incurred as a result of the termination. The termination of the Subscription was due to an adjustment to the Company's wealth management strategies after further consideration by the Company.

The Board is of the view that the termination of the Subscription will have no material adverse impact on the existing business, operational or financial conditions of the Group.

By order of the Board
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
LIU Gexin
Chairman of the Board and Non-executive Director

Hong Kong, January 7, 2026

As at the date of this announcement, the Board comprises Mr. LIU Gexin as the chairman of the Board and non-executive Director, Dr. GE Junyou as executive Director, Mr. LIU Sichuan, Mr. LAI Degui, Mr. FENG Hao, Ms. LIAO Yihong and Mr. ZENG Xuebo as non-executive Directors, and Dr. ZHENG Qiang, Dr. TU Wenwei, Dr. JIN Jinping and Dr. LI Yuedong as independent non-executive Directors.